Claritev Q2 revenue and adj EBITDA beat estimates, raises 2026 outlook
Claritev Q2 revenue and adj EBITDA beat estimates, raises 2026 outlook
Overview
US healthcare data and insights firm's Q2 revenue grew 6.6% yr/yr, beating analyst expectations
Q2 adjusted EBITDA rose 1.1% and beat analyst expectations
Company raised full-year 2026 revenue and adjusted EBITDA guidance
Outlook
Claritev raises FY 2026 revenue guidance to $1 bln-$1.02 bln
Company expects FY 2026 Adjusted EBITDA of $610 mln-$620 mln
Claritev sees FY 2026 free cash flow of $5 mln-$15 mln
Result Drivers
PORTFOLIO EXPANSION - Co said a broader portfolio of solutions and entry into new sales verticals supported revenue growth
STRONG BOOKINGS - Co reported notable strength in bookings, especially in the TPA market, with several large transactions
FAVORABLE MARKET TRENDS - Management said favorable market trends helped drive return to top-line growth
Company press release: ID:nBw2GTYm4a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $257.48 mln | $244.81 mln (4 Analysts) |
Q2 Net Loss |
| $59.23 mln |
|
Q2 Adjusted EBITDA | Beat | $155.80 mln | $147 mln (4 Analysts) |
Q2 Operating Income | Beat | $23.41 mln | $8.70 mln (1 Analyst) |
Q2 Pretax Loss | Beat | $76.65 mln | $91.99 mln (3 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the business support services peer group is "buy"
Wall Street's median 12-month price target for Claritev Corp is $37.50, about 39.7% above its August 6 closing price of $26.84
Reuters Recommended Reads
Aug 6 - CareCloud Q2 revenue rises 16%, slightly beats estimates
Aug 6 - Health Catalyst Q2 adjusted EBITDA beats estimates
Aug 5 - Thomson Reuters lifts full-year revenue forecast with focus on AI rollout
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Claritev
See all newsTPG explores $5 billion sale of healthcare software company Lyric, sources say
Brief: Marpai Expands Relationship With Claritev To Help Reduce Healthcare Costs For Employer Clients
Claritev Corp reports results for the quarter ended June 30 - Earnings Summary
Claritev Q2 revenue and adj EBITDA beat estimates, raises 2026 outlook
Brief: Claritev Corp Q2 Revenue USD 257.478 Million Vs. IBES Estimate USD 244.8 Million